Organon & Co | OGN - Loan Capital


Organon & Co reported $8.55B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Celltrion KRW 411.27B 998.23M Mar/2026
Cspc Pharmaceutical CNY 180.69M 21.94M Dec/2025
Deva Holding AS TRY 559.97M 44.39M Sep/2023
Dianthus Therapeutics USD 0 0 Dec/2024
Divis Laboratories Ltd INR 50M 30M Mar/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
Glaxosmithkline GBP 18.53B 1.29B Mar/2026
Kangmei Pharma CNY 68.57M 9.87M Mar/2026
Knight Therapeutics CAD 57.78M 26.92M Dec/2025
Laboratorios Farma EUR 80.5M 28.26M Dec/2024
Malin Corporation EUR 0 0 Dec/2024
Medical Developments International AUD 1.5M 167K Dec/2025
Merck USD 51.08B 4.41B Jun/2026
Novartis USD 37.45B 7.86B Mar/2026
Organigram Holdings CAD 60.76M 1.77M Mar/2026
Organon & Co USD 8.55B 75M Mar/2026
Ovoca Bio EUR 0 0 Jun/2021
Pharma Mar EUR 32.13M 1.04M Jun/2026
Qiagen NV USD 1.65B 7.87M Mar/2026
Sartorius EUR 3.65B 311.1M Jun/2026
Sino Biopharmaceutical CNY 3.08B 1B Jun/2025
Tilray USD 268.59M 3.82M Sep/2025
Zealand Pharma A/S 307M 76.14M Mar/2026